High-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLC

Clinical trial NCT07182708 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07182708
Sponsor: Peking University Cancer Hospital & Institute
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

NSCLC (Non-small Cell Lung Cancer)EGFR Activating Mutation Resectable Lung Non-Small Cell Carcinoma

Start date: 2025-10-01
Primary completion: 2029-12-30
Enrollment: 62

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.